Raw Incidence of Primary Responsive vs Primary Refractory Patients Among Main B-Cell Lymphoma Subtypes, According to Rituximab Administration.

<p>Blue = responsive, red = fully refractory, brown = early progression, grey = early death. No Rituximab = Chemotherapy without Rituximab; Rituximab = chemotherapy supplemented with Rituximab. DLB-CL: Diffuse Large B-Cell Lymphoma; FL: Follicular Lymphoma; MCL: Mantle-Cell Lymphoma; Miscellaneous B-cell NHL: marginal-zone, small lymphocytic, Burkitt’s and lymphoblastic lymphoma. Data on Rituximab administration were lacking on 21 out of 2,858 B-cell lymphoma patients. <i>p values</i> were calculated for responsive/refractory ratio in No Rituximab compared to Rituximab.